Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Operating Expenses (2016 - 2025)

China Pharma Holdings filings provide 16 years of Operating Expenses readings, the most recent being $1.4 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 30.47% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 19.36% increase, with the full-year FY2025 number at $3.1 million, up 19.36% from a year prior.
  • Operating Expenses hit $1.4 million in Q4 2025 for China Pharma Holdings, up from $568491.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.4 million in Q4 2025 to a low of $309647.0 in Q2 2023.
  • Median Operating Expenses over the past 5 years was $598980.0 (2023), compared with a mean of $722296.1.
  • Biggest five-year swings in Operating Expenses: tumbled 53.38% in 2021 and later skyrocketed 50.24% in 2025.
  • China Pharma Holdings' Operating Expenses stood at $950626.0 in 2021, then increased by 27.46% to $1.2 million in 2022, then decreased by 8.78% to $1.1 million in 2023, then decreased by 6.32% to $1.0 million in 2024, then skyrocketed by 30.47% to $1.4 million in 2025.
  • The last three reported values for Operating Expenses were $1.4 million (Q4 2025), $568491.0 (Q3 2025), and $565110.0 (Q2 2025) per Business Quant data.